ClinicalTrials.gg
RecruitingNCT02577731Updated Jan 15, 2026

Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury

An interventional study of Bone marrow collection and Blood collection in Trauma Injury, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by University of Florida · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jan 2014, registered Oct 2015).
  • Started Jan 2014; still recruiting 12 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Accidental Injuries with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Accidental Injuries · United States.

Planned enrollment
7th of 37
400 · median 72
Started
2014
with 1 other
No phase
26 of 58
7 open now
Primary completion
2026-12
later than 3 of 18 live
Registered
6th of 58
by date
Lead sponsor
5 of 58
University of Florida

Among the 58 studies in Accidental Injuries with a site in United States, this one is the 7th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2014, is one of 26 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 6th registered.

Accidental Injuries

128 studies on the registry are indexed under Accidental Injuries; 39 are open to participants now.

Browse Accidental Injuries studies →

Open to participants now

17 of the 58 studies in Accidental Injuries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Accidental Injuries studies recruiting now, 11 (46%) set no upper age limit and 6 (25%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Accidental Injuries with a site in United States, or all of them as a file.
02

Study summary

Traumatic injury is a leading cause of morbidity and mortality in young adults, and remains a substantial economic and health care burden. Despite decades of promising preclinical and clinical investigations in trauma, investigators understanding of these entities is still incomplete, and few therapies have shown success. During severe trauma, bone marrow granulocyte stores are rapidly released into the peripheral circulation. This release subsequently induces the expansion and repopulation of empty or evacuated space by hematopoietic stem cells (HSCs). Although the patient experiences an early loss of bone marrow myeloid-derived cells, stem cell expansion is largely skewed towards the repopulation of the myeloid lineage/compartment. The hypothesis is that this 'emergency myelopoiesis' is critical for the survival of the severely traumatized and further, failure of the emergency myelopoietic response is associated with global immunosuppression and susceptibility to secondary infection. Also, identifying the release of myeloid derived suppressor cells (MDSCs) in the circulation of human severe trauma subjects. This process is driven by HSCs in the bone marrow of trauma subjects. Additionally, MDSCs may have a profound effect on the nutritional status of the host. The appearance of these MDSCs after trauma is associated with a loss of muscle tissue in these subjects. This muscle loss and possible increased catabolism have huge effects on long term outcomes for these subjects. It is the investigator's goal to understand the differences that occur in these in HSCs and muscle cells as opposed to non-injured and non-infected controls. This work will lead to a better understanding of the myelopoietic and catabolic response following trauma.

Read the detailed description

This is a prospective study to understand how trauma injuries changes the hematopoeitic stem cells (HSCs) in the bone marrow and muscle cells after trauma injury in elderly subjects is different when compared to non-injured subjects.

There will be three groups for this study: 1) Elective hip surgery subjects, 2) Trauma subjects and 3) deidentified bone marrow of healthy controls.

Samples of bone marrow and a blood sample will be collected at the time of surgery. The deidentified bone marrow of healthy controls will come from a tissue bank.

The blood will be used to perform PB colony assays, ELISAs to test for the following parameters: EPO, G-CSF, Reticulocyte, iron levels and cytokines and inflammatory markers.

The bone marrow and blood samples will be processed and sorted to isolate hematopoeitic stem cells for genomic content to determine genomic expression, oxidative stress, mitochondrial activity, apoptosis, autophagy, analysis of circulating erythroid progenitor cells, reticulocytes, granulocyte-colony stimulating factor assays, erythropoietin and iron levels.

Clinical data and hemodynamic measurements will be collected daily while subjects are hospitalized and trauma surgery subjects will be followed to evaluate for malunion and subsequent additional surgical procedures for repair.

03

Conditions studied

  • Trauma Injury

Keywords

  • Trauma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Severe Trauma Population

Inclusion criteria will be:

  1. All adults (age ≥18 to 54)
  2. Blunt and/or penetrating trauma resulting in long bone or pelvic fractures requiring ORIF or closed reduction percutaneous pinning (CRPP).
  3. Blunt and/or penetrating trauma patient with either:

    1. hemorrhagic shock defined by: i. systolic BP (SBP) ≤ 90 mmHg or ii. mean arterial pressure≤ 65 mmHg or iii. base deficit (BD) ≥ 5 meq or iv. lactate ≥ 2
    2. Or injury severity score (ISS) greater than or equal to 15.
  4. All adults (age 55 and older) require:

    1. Blunt and/or penetrating trauma resulting in log bone or pelvic fractures requiring ORIF or CRPP
    2. Either hemorrhagic shock defined by: i. Systolic BP (SBP) ≤ 90 mmHg or ii. Mean arterial pressure ≤ 65 mmHg or iii. Base deficit (BD) ≥5 meq or iv. Lactate ≥ 2
    3. Or Injury Severity Score (ISS) greater than or equal to 15.
  5. Ability to obtain prior to OR repair of injury.

Exclusion Criteria will be:

  1. Patients not expected to survive greater than 48 hours.
  2. Prisoners.
  3. Pregnancy.
  4. Patients receiving chronic or therapies.
  5. Previous bone marrow transplantation.
  6. Patients with End Stage Renal Disease.
  7. Patients with any pre-existing hematological disease.

Elective Hip Repair Population

Inclusion criteria will be:

  1. All adults (age ≥18)
  2. Patient undergoing elective hip repair for non-infectious reasons.
  3. Ability to obtain Informed Consent prior to operation.

Exclusion Criteria will be:

  1. Pregnancy.
  2. Prisoners.
  3. Patients receiving chronic corticosteroids or immunosuppression therapies.
  4. History of receiving Chemotherapy or Radiation within the last 6 months
  5. Previous bone marrow transplantation

7. Patients with End Stage Renal Disease 8. Patients with any pre-existing hematological disease

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Other
    Severe Trauma

    Bone marrow collection. Blood collection. Clinical data collection.

    Other: Bone marrow collection · Other: Blood collection · Other: Clinical data collection

  • Other
    Elective Hip Repair

    Bone marrow collection. Blood collection. Clinical data collection.

    Other: Bone marrow collection · Other: Blood collection · Other: Clinical data collection

  • Other
    Healthy Young Bone Marrow Control

    Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.

    Other: Bone marrow collection

Interventions

  • OtherBone marrow collection

    Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

  • OtherBlood collection

    Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.

  • OtherClinical data collection

    Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.

06

What researchers measure

Primary outcomes

  1. Analyze the genomics response of hematopoietic cells between the groups

    Through negative isolation columns and flow sorting to isolate the hematopoietic stem cells (HSCs) from a sample for appropriate analysis. The sample will then be enriched using a lineage depletion column which will remove all mature hematopoietic cells. The HSCs will be phenotyped and sorted as CD34+ CD38- Thy1+ CD45RA-. HSCs will be lysed and the RNA genomic content will be isolated. The genomic content will then be processed onto a GeneChip® microarray to analyze the genomic expression.

    Time frame: Baseline

  2. Analyze the muscle dysfunction between the groups for oxidative stress

    Time frame: Baseline

  3. Analyze the muscle dysfunction between the groups for mitochondrial activity

    Time frame: Baseline

  4. Analyze the muscle dysfunction between the groups for apoptosis

    Time frame: Baseline

  5. Analyze the muscle dysfunction between the groups for autophagy

    Time frame: Baseline

Secondary outcomes

  1. The pathophysiology of injury-associated persistent anemia through PB colony assays of blood.

    Time frame: Baseline

  2. The pathophysiology of injury-associated persistent anemia through ELISA test of blood.

    Time frame: Baseline

Other outcomes

  1. Analyze the genomics response of hematopoietic cells between the groups at additional follow-up surgery

    Through negative isolation columns and flow sorting to isolate the hematopoietic stem cells (HSCs) from a sample for appropriate analysis. The sample will then be enriched using a lineage depletion column which will remove all mature hematopoietic cells. The HSCs will be phenotyped and sorted as CD34+ CD38- Thy1+ CD45RA-. HSCs will be lysed and the RNA genomic content will be isolated. The genomic content will then be processed onto a GeneChip® microarray to analyze the genomic expression.

    Time frame: Approximately 8 months

  2. Analyze the muscle dysfunction between the groups at additional follow-up surgery for oxidative stress

    Time frame: Approximately 8 months

  3. Analyze the muscle dysfunction between the groups at additional follow-up surgery for mitochondrial activity

    Time frame: Approximately 8 months

  4. Analyze the muscle dysfunction between the groups at additional follow-up surgery for apoptosis

    Time frame: Approximately 8 months

  5. Analyze the muscle dysfunction between the groups at additional follow-up surgery for autophagy

    Time frame: Approximately 8 months

07

Study locations

1 of 1 sites recruiting
  • UF Health Shands Hospital at the University of Florida
    Gainesville, Florida 32610, United States
    Recruiting
    • Jennifer Lanz, MSN · Contactjennifer.lanz@surgery.ufl.edu · 352-273-5497
    • Ruth Davis, ASN · Contactruth.davis@surgery.ufl.edu · 352-273-8759
    • Frederick Moore, MD · Sub investigator
    • Christiaan Leeuwenburgh, PhD · Sub investigator
    • Alicia Mohr, MD · Sub investigator
    • Moldawer Lyle, MD · Sub investigator
    • Kalia Sadasivan, MD · Sub investigator
    • Hari Parvateneni, MD · Sub investigator
    • Philip Efron, MD · Principal investigator
08

References and documents

Publications

  • Munley JA, Willis ML, Gillies GS, Kannan KB, Polcz VE, Balch JA, Barrios EL, Wallet SM, Bible LE, Efron PA, Maile R, Mohr AM. Exosomal microRNA following severe trauma: Role in bone marrow dysfunction. J Trauma Acute Care Surg. 2024 Apr 1;96(4):548-556. doi: 10.1097/TA.0000000000004225. Epub 2023 Dec 28. PubMed 38151766 ↗
  • Munley JA, Kelly LS, Gillies GS, Kannan KB, Pons EE, Bible LE, Efron PA, Mohr AM. EFFECTS OF TRAUMA PLASMA-DERIVED EXOSOMES ON HEMATOPOIETIC PROGENITOR CELLS. Shock. 2023 Apr 1;59(4):591-598. doi: 10.1097/SHK.0000000000002094. Epub 2023 Feb 16. PubMed 36772985 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.

Of 34 non-industry interventional studies with no phase under Accidental Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 51. This study's planned 155 months is above that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 7 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 16, 2015
StartActual
Jan 2014
Primary completionEst.
Dec 28, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02577731
Responsible party
Sponsor
First posted
Oct 16, 2015
Start date
Jan 2014
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Jennifer D Lanz, MSN
Contact
jennifer.lanz@surgery.ufl.edu
352-273-5497
Ruth J Davis, ASN
Contact
ruth.davis@surgery.ufl.edu
352-273-8759
Philip Efron, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion